Merck Operating Income from 2010 to 2025

MRK Stock

USD 87.87 4.44 4.81%

Merck Operating Income yearly trend continues to be quite stable with very little volatility. Operating Income may rise above about 23.8 B this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Merck Company generates from its operations. View All Fundamentals

Operating Income

First Reported

1985-09-30

Previous Quarter

4 B

Current Value

6.8 B

Quarterly Volatility

1.8 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.9 B, Interest Expense of 1.3 B or Total Revenue of 33.3 B, as well as many indicators such as Price To Sales Ratio of 4.32, Dividend Yield of 0.0246 or PTB Ratio of 6.9. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules.

Check out the analysis of Merck Correlation against competitors.

Latest Merck's Operating Income Growth Pattern

Below is the plot of the Operating Income of Merck Company over the last few years. Operating Income is the amount of profit realized from Merck Company operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Merck Company is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Merck's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Merck's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Merck Operating Income Regression Statistics

	Arithmetic Mean	8,325,687,500
	Geometric Mean	5,242,390,261
	Coefficient Of Variation	93.50
	Mean Deviation	6,426,309,375
	Median	5,731,000,000
	Standard Deviation	7,784,572,475
	Sample Variance	60599568.6T
	Range	23.1B
	R-Value	0.73
	Mean Square Error	30206774.8T
	R-Squared	0.53
	Significance	0
	Slope	1,195,701,471
	Total Sum of Squares	908993529.4T

Merck Operating Income History

	2025	23.8 B
	2024	22.7 B
	2023	3 B
	2022	19.4 B
	2021	13.7 B
	2020	6.1 B
	2019	9.2 B

Other Fundumenentals of Merck Company

Non Operating Income Net Other

Merck Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.83	0.32	0.76	0.8	0.87	0.89	0.3	0.81	0.45	0.17	0.89	0.89	0.6	0.58	-0.25	0.3	-0.26	-0.21	0.15	0.24	0.04	0.38	0.32	-0.75	-0.06	0.07	0.06	0.06
Total Stockholder Equity	0.83		0.01	0.6	0.68	0.45	0.89	0.06	0.9	0.1	0.32	0.74	0.74	0.39	0.25	0.14	0.29	-0.18	0.22	-0.04	0.06	0.23	0.58	0.42	-0.45	-0.42	0.04	0.21	0.37
Net Debt	0.32	0.01		0.68	0.57	0.52	0.31	0.13	-0.09	0.81	-0.21	0.48	0.47	0.83	0.81	-0.91	0.52	0.47	-0.6	0.53	0.84	0.5	-0.43	-0.27	-0.53	0.44	0.58	0.51	0.03
Retained Earnings	0.76	0.6	0.68		0.93	0.71	0.85	0.22	0.44	0.82	-0.06	0.88	0.88	0.92	0.89	-0.67	0.68	0.16	-0.46	0.4	0.73	0.52	-0.02	-0.06	-0.7	0.19	0.6	0.48	0.31
Net Receivables	0.8	0.68	0.57	0.93		0.69	0.88	0.17	0.58	0.72	-0.18	0.85	0.85	0.87	0.79	-0.52	0.75	0.19	-0.32	0.39	0.62	0.54	0.17	-0.13	-0.66	0.04	0.58	0.51	0.32
Total Liab	0.87	0.45	0.52	0.71	0.69		0.64	0.4	0.49	0.65	0.01	0.77	0.77	0.64	0.73	-0.53	0.23	-0.25	-0.53	0.27	0.35	-0.12	0.08	0.15	-0.8	0.26	0.09	-0.07	-0.21
Total Current Assets	0.89	0.89	0.31	0.85	0.88	0.64		0.27	0.75	0.46	0.14	0.92	0.92	0.68	0.58	-0.23	0.52	-0.11	-0.13	0.2	0.35	0.35	0.32	0.23	-0.66	-0.11	0.32	0.29	0.29
Short Term Debt	0.3	0.06	0.13	0.22	0.17	0.4	0.27		0.11	0.26	-0.27	0.42	0.42	0.1	0.24	-0.22	0.05	-0.41	-0.48	0.2	-0.09	-0.26	-0.04	0.09	-0.56	0.72	-0.1	-0.36	-0.59
Intangible Assets	0.81	0.9	-0.09	0.44	0.58	0.49	0.75	0.11		0.05	0.16	0.63	0.63	0.23	0.13	0.19	0.22	-0.22	0.14	-0.06	-0.08	0.07	0.75	0.26	-0.46	-0.35	-0.12	0.06	0.15
Accounts Payable	0.45	0.1	0.81	0.82	0.72	0.65	0.46	0.26	0.05		-0.39	0.6	0.59	0.86	0.92	-0.91	0.68	0.34	-0.72	0.47	0.83	0.46	-0.35	-0.42	-0.65	0.52	0.64	0.46	0.07
Short Term Investments	0.17	0.32	-0.21	-0.06	-0.18	0.01	0.14	-0.27	0.16	-0.39		0.12	0.12	-0.18	-0.19	0.4	-0.57	-0.49	0.36	-0.29	-0.3	-0.36	0.24	0.78	0.14	-0.46	-0.49	-0.34	-0.02
Capital Stock	0.89	0.74	0.48	0.88	0.85	0.77	0.92	0.42	0.63	0.6	0.12		1.0	0.73	0.75	-0.42	0.39	-0.22	-0.43	0.31	0.39	0.2	0.22	0.26	-0.71	0.18	0.24	0.12	0.06
Common Stock	0.89	0.74	0.47	0.88	0.85	0.77	0.92	0.42	0.63	0.59	0.12	1.0		0.73	0.75	-0.41	0.38	-0.23	-0.43	0.31	0.39	0.2	0.23	0.27	-0.7	0.18	0.24	0.12	0.05
Long Term Debt	0.6	0.39	0.83	0.92	0.87	0.64	0.68	0.1	0.23	0.86	-0.18	0.73	0.73		0.93	-0.76	0.73	0.34	-0.48	0.43	0.89	0.61	-0.23	-0.18	-0.59	0.2	0.68	0.59	0.28
Good Will	0.58	0.25	0.81	0.89	0.79	0.73	0.58	0.24	0.13	0.92	-0.19	0.75	0.75	0.93		-0.84	0.56	0.16	-0.73	0.51	0.81	0.39	-0.23	-0.17	-0.58	0.44	0.57	0.37	0.1
Treasury Stock	-0.25	0.14	-0.91	-0.67	-0.52	-0.53	-0.23	-0.22	0.19	-0.91	0.4	-0.42	-0.41	-0.76	-0.84		-0.54	-0.45	0.76	-0.56	-0.81	-0.42	0.52	0.45	0.56	-0.61	-0.65	-0.42	-0.03
Property Plant Equipment	0.3	0.29	0.52	0.68	0.75	0.23	0.52	0.05	0.22	0.68	-0.57	0.39	0.38	0.73	0.56	-0.54		0.65	-0.22	0.4	0.74	0.84	-0.09	-0.63	-0.44	0.1	0.87	0.83	0.46
Current Deferred Revenue	-0.26	-0.18	0.47	0.16	0.19	-0.25	-0.11	-0.41	-0.22	0.34	-0.49	-0.22	-0.23	0.34	0.16	-0.45	0.65		0.06	0.3	0.62	0.82	-0.34	-0.67	0.01	-0.06	0.7	0.88	0.57
Net Tangible Assets	-0.21	0.22	-0.6	-0.46	-0.32	-0.53	-0.13	-0.48	0.14	-0.72	0.36	-0.43	-0.43	-0.48	-0.73	0.76	-0.22	0.06		-0.51	-0.44	0.02	0.23	0.33	0.4	-0.83	-0.29	0.09	0.38
Total Permanent Equity	0.15	-0.04	0.53	0.4	0.39	0.27	0.2	0.2	-0.06	0.47	-0.29	0.31	0.31	0.43	0.51	-0.56	0.4	0.3	-0.51		0.45	0.33	-0.01	-0.37	-0.32	0.33	0.41	0.3	0.06
Long Term Debt Total	0.24	0.06	0.84	0.73	0.62	0.35	0.35	-0.09	-0.08	0.83	-0.3	0.39	0.39	0.89	0.81	-0.81	0.74	0.62	-0.44	0.45		0.74	-0.44	-0.42	-0.35	0.24	0.77	0.75	0.37
Capital Surpluse	0.04	0.23	0.5	0.52	0.54	-0.12	0.35	-0.26	0.07	0.46	-0.36	0.2	0.2	0.61	0.39	-0.42	0.84	0.82	0.02	0.33	0.74		-0.17	-0.49	-0.12	-0.09	0.82	0.95	0.68
Deferred Long Term Liab	0.38	0.58	-0.43	-0.02	0.17	0.08	0.32	-0.04	0.75	-0.35	0.24	0.22	0.23	-0.23	-0.23	0.52	-0.09	-0.34	0.23	-0.01	-0.44	-0.17		0.17	0.04	-0.38	-0.35	-0.19	0.0
Long Term Investments	0.32	0.42	-0.27	-0.06	-0.13	0.15	0.23	0.09	0.26	-0.42	0.78	0.26	0.27	-0.18	-0.17	0.45	-0.63	-0.67	0.33	-0.37	-0.42	-0.49	0.17		0.01	-0.3	-0.63	-0.49	-0.11
Accumulated Depreciation	-0.75	-0.45	-0.53	-0.7	-0.66	-0.8	-0.66	-0.56	-0.46	-0.65	0.14	-0.71	-0.7	-0.59	-0.58	0.56	-0.44	0.01	0.4	-0.32	-0.35	-0.12	0.04	0.01		-0.3	-0.23	-0.14	0.14
Short Long Term Debt	-0.06	-0.42	0.44	0.19	0.04	0.26	-0.11	0.72	-0.35	0.52	-0.46	0.18	0.18	0.2	0.44	-0.61	0.1	-0.06	-0.83	0.33	0.24	-0.09	-0.38	-0.3	-0.3		0.15	-0.17	-0.54
Cash And Equivalents	0.07	0.04	0.58	0.6	0.58	0.09	0.32	-0.1	-0.12	0.64	-0.49	0.24	0.24	0.68	0.57	-0.65	0.87	0.7	-0.29	0.41	0.77	0.82	-0.35	-0.63	-0.23	0.15		0.79	0.55
Net Invested Capital	0.06	0.21	0.51	0.48	0.51	-0.07	0.29	-0.36	0.06	0.46	-0.34	0.12	0.12	0.59	0.37	-0.42	0.83	0.88	0.09	0.3	0.75	0.95	-0.19	-0.49	-0.14	-0.17	0.79		0.73
Net Working Capital	0.06	0.37	0.03	0.31	0.32	-0.21	0.29	-0.59	0.15	0.07	-0.02	0.06	0.05	0.28	0.1	-0.03	0.46	0.57	0.38	0.06	0.37	0.68	0.0	-0.11	0.14	-0.54	0.55	0.73

Click cells to compare fundamentals

About Merck Financial Statements

Merck investors utilize fundamental indicators, such as Operating Income, to predict how Merck Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	22.7 B	23.8 B
Non Operating Income Net Other	-1.4 B	-1.3 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Merck Correlation against competitors.

You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.33)

Dividend Share

3.08

Earnings Share

6.74

Revenue Per Share

25.343

Quarterly Revenue Growth

0.068

The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Operating Income from 2010 to 2025

Latest Merck's Operating Income Growth Pattern

Merck Operating Income Regression Statistics

Merck Operating Income History

Other Fundumenentals of Merck Company

Merck Operating Income component correlations

About Merck Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY